Pharmacokinetics of CPT-11 in rhesus monkeys

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 2, 1997, Pages 103-108

  Inaba, Makoto ^a   Ohnishi, Yasuyuki ^b   Ishii, Hajime ^b   Tanioka, Yoshikuni ^b   Yoshida, Yasushi ^c   Sudoh, Kenichi ^c   Hakusui, Hideo ^c   Mizuno, Naomi ^d   Ito, Kiyomi ^d   Sugiyama, Yuichi ^d  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^c DAIICHI SANKYO CO   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

CPT 11; Monkey; Pharmacokinetics

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISPOSITION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MEAN RESIDENCE TIME; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY;

EID: 6844254547     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050715     Document Type: Article

References (21)

1. Canal P, Gay C, Dezeuze A, Douillard JY, Bugat R, Adenis A, Herait P, Lokiec F, Mathieu-Boue A (1996) Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 14: 2688-2695
2. Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra J-M, Mahjoubi M, Herait P, Armand J-P, Bugat R, Clavel M, Marty ME (1995) Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 6: 141-151
3. Collins JM, Zaharko DS, Dedrick RL, Chabner BA (1986) Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 70: 73-80
4. Dancey J, Eisenhauer EA (1996) Current perspectives on camptothecins in cancer treatment. Br J Cancer 74: 327-338
5. Fuse E, Kobayashi S, Inaba M, Suzuki H, Sugiyama Y (1994) Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity. J Natl Cancer Inst 86: 989-996
6. Inaba M, Mitsuhashi J, Kawada S, Nakano H (1994) Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis. Jpn J Cancer Res 85: 187-193
7. Kaneda N, Yokokura T (1990) Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 50: 1721-1725
8. Kaneda N, Nagata H, Furuta T, Yokokura T (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50: 1715-1720
9. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H, Taguchi T (1991) Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83: 1164-1168
10. Ozawa S, Sugiyama Y, Mitsuhashi Y, Kobayashi T, Inaba M (1988) Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product. Cancer Chemother Pharmacol 21: 185-190
11. Ozawa S, Sugiyama Y, Mitsuhashi J, Inaba M (1989) Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells. Cancer Res 49: 3823-3828
12. Rivory LP, Chatelut E, Canal P, Mathieu-Boue A, Robert J (1994) Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res 54: 6330-6333
13. Rivory LP, Bowles MR, Robert J, Pond SM (1996) Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 52: 1103-1111
14. Rothenberg ML, Kuhn JG, Burris III HA, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI, Rock MK, Von Hoff DD (1993) Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11: 2194-2204
15. Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen T-L, Rock MK, Donehower RC (1994) Phase 1 pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54: 427-436
16. Sasaki Y, Hakusui H, Mizuno S, Morita M, Miya T, Eguchi K, Shinkai T, Tamura T, Ohe Y, Saijo N (1995) A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res 86: 101-110
17. Sasaki Y, Yoshida Y, Sudoh K, Hakusui H, Fujii H, Ohtsu T, Wakita H, Igarashi T, Itoh K (1995) Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn J Cancer Res 86: 111-116
18. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, Nagai E (1994) Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 17: 662-664
19. Suzuki W, Atsumi T, Nakaoka M, Hakusui H (1990) Metabolic fate of CPT-11 in beagle dogs after single bolus injection and infusion (in Japanese). The Clin Rep 24: 219-228
20. Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T, Tsuru D (1991) CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobio-Dyn 14: 341-349
21. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4: 879-885